Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. has demonstrated a strong performance in Q3 FY25, with revenues reaching $6.8 million, reflecting a remarkable 76% year-over-year increase and a 78% sequential rise, largely driven by the integration of the SCN model, which has accelerated revenue growth with minimal additional investment. The company's service revenue also saw significant growth, more than doubling to $4.6 million, indicating successful contributions from sleep testing and treatment-center revenues. Additionally, the improvement rates among patients, with up to 93% of those with severe OSA achieving a 50% improvement, highlight the effectiveness of the Vivos System, positioning the company favorably in a market that is poised for expansion, particularly in North America and the Asia Pacific region.

Vivos Therapeutics Inc is experiencing significant financial challenges, illustrated by a year-over-year revenue decline of 9% in the first half of 2025, attributed largely to its transition to a direct sleep center management model. Gross margins have also decreased to 55% in the second quarter of 2025 due to discounting and changes in the product and service mix, indicating pressures on profitability. Furthermore, the company faces substantial risks including lower-than-expected sales growth, difficulties in securing capital, a history of operating losses, and ongoing uncertainty about achieving sustainable profitability, all of which contribute to a negative outlook for the stock.